Voyager醫療 VYGR 深 滬
等待開盤 10-14 09:30:00 美东时间
4.89
-0.110
-2.20%
華盛通- 最 高5.15
- 今 開5.10
- 成交量 71.87万股
- 最 低 4.8242
- 昨 收 5.00
- 總市值 2.71亿
- 52周最高 8.17
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.645
- 委 比 -50.96%
- 總股本 5533.64万
- 歷史最高 31.91
- 量 比 0.65
- 振 幅 6.52%
- 歷史最低 2.46
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.
09-16 02:00
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 price target.
09-15 19:11
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in several upcoming investor conferences to discuss its non-viral delivery platform for neurotherapeutics. The company will present at events including Citi's Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. We...
08-26 11:00
基因疗法“一劳永逸”?跨国药企争抢布局：罗氏、诺华、渤健……
（来源：动脉新医药） 近年来，以AAV为主流载体的基因疗法凭借其“一劳永逸”的独特优势，让全球生物医药企业玩家争抢着上牌桌。 从耳朵到大脑、从眼睛...
08-18 18:18
Wedbush Maintains Outperform on Voyager Therapeutics, Lowers Price Target to $8
Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowers the price target from $9 to $8.
08-07 20:43
Voyager Therapeutics Q2 EPS $(0.57) Misses $(0.54) Estimate, Sales $5.20M Miss $9.91M Estimate
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.54) by 5.95 percent. This is a 216.67 percent decrease over losses of $(0.18) per share
08-07 04:52
Voyager Therapeutics Introduced A Wholly-Owned Program That Modulates The Expression Of Apolipoprotein E For Alzheimer's Disease
New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant.Voyager's wholly-owned Alzheimer's
07-16 19:02
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager Therapeutics has expanded its Alzheimer’s disease (AD) franchise with a new program targeting apolipoprotein E (APOE), the strongest genetic risk factor for AD. The program uses a proprietary IV-delivered TRACER capsid to deliver a bifunctional payload that silences APOE4, linked to higher AD risk, while delivering APOE2, associated with lower risk. Preclinical studies show significant reduction of APOE4 and increase of APOE2 in AD-releva...
07-16 11:00
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics announced that its CEO and management will participate in a fireside chat at the H.C. Wainwright Neuro Perspectives Conference. A live webcast will be available on June 17 at 7:00 a.m. ET on the company’s website, and it will remain archived for at least 30 days. Voyager is focused on using human genetics to treat and cure neurological diseases like Alzheimer’s, Parkinson’s, and ALS, utilizing its TRACER AAV capsid discovery ...
06-10 11:00
